RVL Pharmaceuticals plc reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 8.26 million compared to USD 8.45 million a year ago. Net loss was USD 23.89 million compared to USD 12.11 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.14 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 0.14 a year ago.
For the six months, revenue was USD 17.09 million compared to USD 29.89 million a year ago. Net loss was USD 35.5 million compared to USD 18.93 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.23 a year ago.